A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients.

Trial Profile

A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Dianexin (Primary)
  • Indications Embolism and thrombosis; Transplant rejection
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 26 Oct 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 05 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top